Breaking News

Trials & Filings in Brief: Nov. 7, 2013

By Gil Roth | November 7, 2013

Agenus, Bayer, Celgene, Galderma, Genentech, NovaBay, Omeros, Regeneron, Roche

Phase I
Omeros TMA treatment well tolerated . . . read more

Phase II
Agenus posts good herpes vax results . . . read more

NovaBay impetigo treatment misses endpoint . . . read more

Phase III
Celgene to present Revlimid data at ASH . . . read more

Gazyva wallops Rituxan in CLL trial . . . read more

Bayer files for DME indication for Eylea . . . read more
  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks

  • The Growing Realm of Real-World Data

    Kristin Brooks, Contract Pharma||November 8, 2016
    PPD's Evidera acquisition aims to help clients address the growing demand for evidence from regulators and payers

  • Mastering Immunotherapy Clinical Trials: Dosing and Response

    Mastering Immunotherapy Clinical Trials: Dosing and Response

    Kristin Brooks, Contract Pharma||August 1, 2016
    Andrew Zupnick of Novella Clinical provides insights into dosing and measuring response in immunotherapy clinical trials